1 April 2020 in Drug Design, Development and Therapy
Introduction: As a worldwide health issue, the treatment and prevention of atherosclerosis present an important goal. Increased levels of proinflammatory cytokines such as TNF-α-associated chronic inflammatory response cause endothelial cells to lose their ability to regulate vascular function. Lipid-laden immune cells are recruited to the endothelium where they adhere to the endothelial wall and invade the intimal space, thereby leading to the development of atherosclerotic lesions, fatty plaques, and thickening of the arterial wall. In the present study, for the first time, we investigated the effects of laquinimod, an immunomodulatory agent used for the treatment of multiple sclerosis, on human aortic endothelial in a TNF-α-induced atherosclerotic microenvironment. At present, the mechanism of action of laquinimod is not well defined. Methods: The effects of laquinimod on the gene expression of IL-6, MCP-1, VCAM-1, E-selectin, and KLF2 were measured by real-time PCR. ELISA assay was used to determine protein secretion and expression. Phosphorylation of ERK5 and the protein level of KLF2 were measured by Western blot analysis. The attachment of monocytes to endothelial cells was assayed by calcein-AM staining and fluorescent microscopy. Results: Our findings demonstrate that laquinimod reduced the expression of key inflammatory cytokines and chemokines, including IL-6, MCP-1, and HMGB1. We further demonstrate that laquinimod significantly reduced the attachment of monocytes to endothelial cells, which is mediated through reduced expression of the cellular adhesion molecules VCAM-1 and E-selectin. Here, we found that laquinimod could significantly increase the expression of KLF2 through activation of ERK5 signaling. The results of our KLF2 knockdown experiment confirm that the effects of laquinimod observed in vitro are dependent on KLF2 expression. Conclusion: Together, these findings suggest a potential antiatherosclerotic capacity of laquinimod. Further research will elucidate the underlying mechanisms.
21 November 2022 in Evidence-Based Complementary and Alternative Medicine
Although heart failure (HF) has become one of the most fatal diseases in the whole world, there are fewer drugs for its treatment. Therefore, we focused on the protective effect of Dl-3-n-butylphthalide (NBP) on myocardial injury and oxidative stress in heart failure mice and further investigated the relationship with the Nrf2/HO-1/Ca2+-SERCA2a axis. Methods. C57BL/6J mice were divided into the sham group (Sham), heart Failure model group (HF), HF+NBP group (HN), HN+Nrf2 inhibitor (HNM), HN+Calmodulin-dependent protein kinase II (CaMKII) antagonist, KN93 (HNK). The HF mice model was prepared using abdominal aorta ligation. Mices heart function was accessed by echocardiography. Hematoxylin-eosin staining and MASSON staining were used to identify myocardial injury; the cell apoptosis was determined by the TUNEL staining assay. The expression of oxidative stress-related proteins was detected by the ELISA assay. The reactive oxygen species and Nrf2 expression in heart tissue were observed with the immunofluorescence assay. SERCA2a, calmodulin, endoplasmic reticulum stress regulatory proteins, and Nrf2/HO-1 in mice heart tissues were measured using Western blotting. Results. Moreover, NBP could significantly promote heart failure mices heart function, relieve the injury and inhibit cell apoptosis. Meanwhile, it could reduce ERS injury of heart failure mice through increasing SERCA2a level and reducing Ca2+ influx. NBP was demonstrated to minimize CaMKII phosphorylation level and decrease cAMP-response element-binding protein phosphorylation level, suggesting NBP could also activate the Nrf2/HO-1 signaling pathway. Conclusions. We demonstrated that NPBs treatment promotes the cardiomyocytes ERS and alleviates myocardial injury in heart failure mice, related to stimulating the Nrf2/HO-1 signaling pathway, regulating Ca2+-SERCA2a, and reducing Ca2+ influx.
5 September 2020 in Neural Computing and Applications
31 March 2020 in IEEE Access
Presently, Coronary Acute Syndrome (CAS) is a widespread and extreme heart disease which is considered as one of the major concerns for death in the world with long-term disability. For early intervention and care, the prediction of CAS clinical risk is more critical during analysis. A minimum number of manually selected dimensions of risk are used for current CAS risk assessment models and statistical variables are often dichotomized to optimize storage in the Internet of medical things platform(IoMT) on the Encoder layer during data analysis. This research develops a Convolution Denoising Regularized Auto Encoder Stacked Method (CDRAESM) to normalize CAS patient’s medical risks from high volumes of patient records and the characteristics have been analyzed during prediction. In this research, a true medical dataset of 3,464 CAS samples is used for experimental analysis and numerical reliability has been analyzed in Area Characteristics Curve (ACC) with an Accuracy range of 96.77%. The results show that the current health risk prediction using CDRAESM achieves competitive concert than conventional models which prevails in practice. Further, the reconstructive learning strategy approach can extract informational risk from the CAS and the risk factors has been identified with existing knowledge of the clinical domain and include theories that might be confirmed by further medical research.